IL13RA2 and neoplasm: In one patient with multiple lesions with meningeal disseminations, who received repeated intraventricular administration of IL-13Rα2 CAR T-cells, persistence of the CAR T-cells was seen in the CSF for at least 7 days after the last intracranial infusion, and the patient had a complete response for 7 months before the tumor recurred.